首页> 外文期刊>Acta tropica: Journal of Biomedical Sciences >Serum levels of sTNF-R1, sTNF-R2 and CXCL9 correlate with disease activity in adult type paracoccidioidomycosis.
【24h】

Serum levels of sTNF-R1, sTNF-R2 and CXCL9 correlate with disease activity in adult type paracoccidioidomycosis.

机译:在成人型副球孢子菌病中,血清sTNF-R1,sTNF-R2和CXCL9的水平与疾病活动相关。

获取原文
获取原文并翻译 | 示例
           

摘要

Paracoccidioidomycosis (PCM) is the most common systemic mycosis in Latin America. A major problem in the management of PCM is to determine the best time to discontinue therapy due to the high relapse rate among patients. Soluble TNF receptors (sTNF-R) levels and chemokines are associated with disease activity in several infectious, inflammatory and autoimmune disorders. The aim of the present work was to evaluate levels of sTNF-R1, sTNF-R2 and chemokines in serum of patients with adult type of PCM, before and after antifungal therapy, and to correlate those levels to disease activity. Concentrations of sTNF-R1, sTNF-R2 and CXCL9 were higher in untreated patients and decreased progressively with treatment. The serum marker with the best accuracy to discriminate PCM cases from controls was sTNF-R2. sTNF-R1 did not drop to control levels before 36 months of treatment. CCL2 and CCL3 levels were low at baseline in PCM patients, raised significantly after 12 months of treatment and diminished thereafter. CCL24 levels were higher after 36 months of antifungal therapy in PCM patients. CCL11 levels were not statistically different from control subjects. sTNF-R1, sTNF-R2 and CXCL9 may be useful as laboratory parameters to assess disease activity in PCM patients.
机译:副球菌病(PCM)是拉丁美洲最常见的全身性真菌病。由于患者中的高复发率,PCM治疗中的主要问题是确定停止治疗的最佳时间。在几种传染性,炎性和自身免疫性疾病中,可溶性TNF受体(sTNF-R)水平和趋化因子与疾病活动有关。本研究的目的是评估抗真菌治疗前后成年型PCM患者血清中sTNF-R1,sTNF-R2和趋化因子的水平,并将这些水平与疾病活动相关联。 sTNF-R1,sTNF-R2和CXCL9的浓度在未经治疗的患者中较高,并随治疗而逐渐降低。能够最准确地区分PCM病例与对照组的血清标志物是sTNF-R2。在治疗36个月之前,sTNF-R1并未降至对照水平。 PCM患者的CCL2和CCL3水平在基线时较低,在治疗12个月后显着升高,此后降低。 PCM患者经过36个月的抗真菌治疗后,CCL24水平更高。 CCL11水平与对照组无统计学差异。 sTNF-R1,sTNF-R2和CXCL9可用作评估PCM患者疾病活动的实验室参数。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号